Last month, in a decision by the Northern District of California in Ariosa Diagnostics v. Sequenom, the court
granted summary judgment of invalidity for claims directed to non-invasive prenatal diagnosis
GlaxoSmithKline (GSK) has launched a global consortium
consisting of itself and six internationally renowned comprehensive cancer centers based in the United States, Canada and Europe to collaborate on a
scientific research network aimed at focusing on oncology clinical trials and combination drug therapies, as well as translational research
The magazine's new chief editor gives you a brief introduction to
himself but mostly offers a tour around the new format because in 2014, instead of news sections based on therapeutic, technological and research areas, our
sections will be based on the pipeline stages that most of you deal with in your day-to-day work.
As DDNews Feature Editor Randy Willis notes, he and several others
have harped over the years that the needs and practical realities of patients in the developing world are significantly different from those in the developed
world. While that statement may sound patently obvious and therefore ridiculous, it has significant implications when it comes to delivering useful and
sustainable healthcare, and he tells you why.
In two recent decisions, different panels of the Federal Circuit reaffirmed the
importance of the written description requirement of 35 U.S.C. § 112(a). These cases underscore the importance of the written-description requirement, and
suggest that the Federal Circuit may be inclined to reject as invalid broad claims covering solutions to problems not described in the patent.